NCD enhances CD8+ T cell–mediated antitumor immunity by upregulating TIME-GES genes and targeting the JAK2-STAT3 signaling pathway, resulting in suppressed tumor growth and reprogramming of the TIME toward a more immunologically active, “hot” phenotype. Here, JAK2 is linked to neoplasm.